Health & Fitness
Fri, May 7, 2010Thu, May 6, 2010Mon, January 11, 2010Sat, January 9, 2010Fri, January 8, 2010Thu, January 7, 2010Wed, January 6, 2010Tue, January 5, 2010Mon, January 4, 2010Thu, December 31, 2009Wed, December 30, 2009Tue, December 29, 2009Mon, December 28, 2009Thu, December 24, 2009Wed, December 23, 2009Tue, December 22, 2009Mon, December 21, 2009Fri, December 18, 2009Thu, December 17, 2009Wed, December 16, 2009Tue, December 15, 2009Novo Nordisk A/S: Research Update
Published in Health and Fitness on Wednesday, December 30th 2009 at 1:00 GMT by Market Wire
BAGSVAERD, DENMARK--(Marketwire - December 30, 2009) - Update on timeline for formal feedback on liraglutide from the FDA
Novo Nordisk today announced that formal feedback from the United States Food and Drug Administration (FDA) regarding liraglutide, a once-daily human GLP-1 analogue, is expected within weeks. Novo Nordisk continues the constructive dialogue with the FDA regarding the regulatory process for liraglutide.
Novo Nordisk expects to provide an update on the regulatory process for liraglutide in connection with the announcement of the financial results for 2009 on 2 February 2010, if formal feedback is not received before then.
About liraglutide
Liraglutide is the first once-daily human Glucagon-Like Peptide-1 (GLP-1) analogue developed for the treatment of type 2 diabetes. Liraglutide works by stimulating the release of insulin only when glucose levels become too high and by inhibiting appetite. On 23 May 2008, Novo Nordisk submitted a New Drug Application to the Food and Drug Administration in the US for the approval of liraglutide for the treatment of people with type 2 diabetes. In Europe, Novo Nordisk received marketing authorisation for liraglutide under the brand name Victoza® on 30 June, and Victoza® has subsequently been launched. A New Drug Application was also submitted for approval in Japan on 14 July 2008.
Novo Nordisk is a healthcare company and a world leader in diabetes care. In addition, Novo Nordisk has a leading position within areas such as haemostasis management, growth hormone therapy and hormone replacement therapy. Novo Nordisk manufactures and markets pharmaceutical products and services that make a significant difference to patients, the medical profession and society. With headquarters in Denmark, Novo Nordisk employs more than 29,000 employees in 81 countries, and markets its products in 179 countries. Novo Nordisk's B shares are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed on the New York Stock Exchange under the symbol 'NVO'. For more information, visit novonordisk.com
Further information: Media: Investors: Mike Rulis Mads Veggerby Lausten Tel: (+45) 3079 3573 Tel: (+45) 4443 7919 [ mike@novonordisk.com ][ mlau@novonordisk.com ] Kasper Roseeuw Poulsen Tel: (+45) 3079 4471 [ krop@novonordisk.com ] In North America: In North America: Sean Clements Hans Rommer Tel: (+1) 609 514 8316 Tel: (+1) 609 216 4834 [ secl@novonordisk.com ][ hrmm@novonordisk.com ]
Company Announcement no 75 / 2009
